The OPTIMA Study
Piergiorgio Messa(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Francesco Locatelli(University of Modena and Reggio Emilia), Willem Jan W. Bos(St. Antonius Ziekenhuis), Francisco Maduell, Koen Bouman, J. Braun(KfH Kuratorium für Dialyse und Nierentransplantation), Helmut Reichel(Heidelberg University), B Albertini, Martin Wilkie(Sheffield Teaching Hospitals NHS Foundation Trust), Hans Brink, Dave Carter(AstraZeneca (United Kingdom)), Heikki Saha(Tampere University Hospital), Magdi Yaqoob(Queen Mary University of London), Vicente Torregrosa, Helmut Graf(University of Vienna), Valter J. Zani(Amgen (United States)), Bart Molemans(Amgen (United States))
Cited by 225
Related Papers
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
|Data Archiving and Networked Services (DANS)|2003|2.5k
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
|New England Journal of Medicine|2006|2.1k
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
|New England Journal of Medicine|2004|1.1k
The burden of kidney disease: Improving global outcomes
|Kidney International|2004|521
Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement
|Nephrology Dialysis Transplantation|2013|476